# Matchpoint Therapeutics

> Precision covalent medicines for autoimmune and inflammatory diseases.

## Why it is interesting

Matchpoint combines chemical biology, covalent chemistry, structure-based design and computation in a platform that has already attracted a Novartis collaboration and a large preclinical Series B.

## Profile

- **Latest funding:** Series B — $150M (October 7, 2026)
- **Latest known valuation:** Not publicly disclosed
- **Total disclosed equity funding:** $150M
- **Stage:** series-b
- **Status:** private
- **Industries:** biotech-life-sciences, healthtech
- **Coverage:** full
- **Last updated:** 2026-10-08T20:12:00.000Z
- **Latest funding investors:** Nextech Invest, Norwest, Invus, BB Biotech, T1D Fund, BOLD Longevity Growth, Access Biotechnology, Atlas Venture, Sanofi Ventures, Digitalis Ventures

## Key facts

- Closed a $150 million Series B in October 2026.
- Has a separate discovery collaboration funded by Novartis.

## Funding history

- Series B · $150M · October 7, 2026
  Source: https://matchpointtx.com/news/matchpoint-therapeutics-announces-150-million-series-b-financing-to-advance-pipeline-of-first-in-class-oral-small-molecules-for-autoimmune-and-inflammatory-diseases/

## Investors in our directory

- https://venturecapitaltracker.com/fund/nextech-invest
- https://venturecapitaltracker.com/fund/norwest

## Related articles

- https://venturecapitaltracker.com/2026-matchpoint-therapeutics-150m-series-b-mpt-062

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)
**Last updated:** October 8, 2026

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.

---
Source: https://venturecapitaltracker.com/startup/matchpoint-therapeutics